Graft Versus Host Disease (GvHD) Pipeline Guide, H1 2020

News provided by

Apr 27, 2020, 09:15 ET

DUBLIN, April 27, 2020 /PRNewswire/ -- The "Graft Versus Host Disease (GvHD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

The guide provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GvHD) and features dormant and discontinued projects.

Furthermore, it covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 39, 11, 3, 43, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

Key Topics Covered

Introduction
Overview
Therapeutics Development
Therapeutics Assessment
Companies Involved in Therapeutics Development
Drug Profiles
Dormant Projects
Discontinued Products
Product Development Milestones
Appendix

Companies Mentioned

AbbVie Inc
AbGenomics International Inc
Adienne Pharma & Biotech
Alpine Immune Sciences Inc
Amgen Inc
AnaptysBio Inc
apceth Biopharma GmbH
ASC Therapeutics Inc
AstraZeneca Plc
Athersys Inc
Autolus Therapeutics Plc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
BlueRock Therapeutics
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cellix Bio Pvt Ltd
CheckPoint Immunology Inc
Clinigen Group Plc
CSL Ltd
CTI BioPharma Corp
Cytodyn Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dualogics Corp
Eli Lilly and Co
Elsalys Biotech SA
enGene Inc
Enlivex Therapeutics Ltd
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Generon (Shanghai) Corp Ltd
GigaGen Inc
GlaxoSmithKline Plc
Glia LLC
Humanigen Inc
Immplacate
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Corp LLC
Kalytera Therapeutics Inc
Kamada Ltd
Kiadis Pharma NV
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
LG Chem Ltd
MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medac Pharma Inc
Medicenna Therapeutics Corp
Medsenic SAS
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
NapaJen Pharma Inc
Neovii Pharmaceuticals AG
Novartis AG
Ocugen Inc
OncoImmune Inc
OSE Immunotherapeutics
Panorama Research Inc
Pfizer Inc
Pharmicell Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
REGiMMUNE Corp
Sanofi
SCM lifescience Co Ltd
Seattle Genetics Inc
Secura Bio Inc
STERO Biotechs Ltd
Suzhou Connect Biopharmaceuticals Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Taiwan Bio Therapeutics Co Ltd
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TCF GmbH
TeraImmune Inc
TGV Laboratories Inc
United BioPharma Inc
Vault Pharma Inc
VBI Vaccines Inc
Visterra Inc
Xenikos BV
Xenothera SAS
XL-protein GmbH

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2ty6mw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets